Home/Pipeline/PTT-4256

PTT-4256

Solid Tumors

Phase 1Active

Key Facts

Indication

Solid Tumors

Phase

Phase 1

Status

Active

Company

Pathios Therapeutics

About Pathios Therapeutics

Pathios Therapeutics is a UK-based, clinical-stage biotech leveraging human genetics to develop first-in-class GPR65 inhibitors for cancer. The company's science centers on the acidic tumor microenvironment (TME), which activates GPR65 on immune cells like macrophages, T cells, and NK cells, driving them into a pro-tumorigenic state. By inhibiting GPR65, Pathios aims to reverse this immunosuppression at its root cause, potentially restoring anti-tumor immunity and enhancing the efficacy of existing immunotherapies. The company is advancing its lead oral candidate, PTT-4256, into clinical development for solid tumors.

View full company profile

Therapeutic Areas

Oncology Immunology

Other Solid Tumors Drugs

Drug	Company	Phase	Status
APVO603	Aptevo Therapeutics	Preclinical	Active
APVO711	Aptevo Therapeutics	Preclinical	Active
Platform-derived Immunotherapy	GenCirq	Pre-clinical	Active
DM001	Domabio	Phase 1	Active (IND cleared in US and China)
DM002	Domabio	Phase 1	Active (IND cleared in US)
DM005	Domabio	Phase 1	Active (IND cleared in US, Australia, and China; first patient dosed in US)
SP-2-225	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
SP-1-161	Shuttle Pharmaceuticals	Preclinical	Candidate Lead
CAR-T Solid Tumor Program	Carina Biotech	Phase 1/2a	Active
HBM1020	Harbour BioMed	Phase 1	Active (Global)
HBM7022	Harbour BioMed	Phase 1	Out-Licensed
HBM9033	Harbour BioMed	Discovery	Out-Licensed